QLT (QLTI) Said The FDA To Review Aczone labeling supplement

July 23, 2007 7:26 AM EDT

QLT Inc. (NASDAQ: QLTI) said the FDA has accepted for filing and review QLT USA, Inc.'s labeling supplement for Aczone to request the removal of the glucose-6-phosphate dehydrogenase screening and blood monitoring requirements from its current label. A decision by the FDA on the label revision is expected by the end of March 2008.


Related Categories

FDA

Stocks Mentioned

QLTI 2.13

-0.01 -0.47%
Volume: 94,641
Track QLTI


Add Your Comment